RhoB GTPase and FTIs in Cancer

  • Minzhou Huang
  • Lisa D. Laury-Kleintop
  • George C. Prendergast


RhoB, a member of the Rho family of small GTPases that localizes mainly to endosomes, regulates cytoskeletal actin organization, vesicle trafficking, cell proliferation, and cell survival. In cultured cells, RhoB expression is often low but rapidly upregulated by a variety of stimuli including UV irradiation, growth factors, cytokines, steroids, and toxins. By controlling endosomal trafficking, RhoB influences a number of important oncogenic signaling pathways, including pathways that control Src, Akt/PKB, NF-κB, and Myc. In various types of cancer, RhoB expression is frequently attenuated, especially after malignant progression. Additionally, RhoB plays an important role in facilitating apoptosis of neoplastically transformed cells by farnesyltransferase inhibitors (FTIs), DNA damaging drugs, microtubule disrupting agents, and other cancer therapeutics. Genetic studies of RhoB in mice reinforce the concept of this gene as a cancer suppressor or negative modifier gene; however, recent findings demonstrate that RhoB supports the proliferation and survival of vascular endothelial and smooth muscle cells. Ongoing investigations aim at deepening our understanding of the unique functions of RhoB with the goal of exploiting them for therapeutic applications.


Epidermal Growth Factor Receptor HDAC Inhibitor Vesicle Trafficking PDGF Receptor Actin Reorganization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992a) Post-translational modifications of p21rho proteins. J Biol Chem 267:20033–20038.Google Scholar
  2. Adamson P, Paterson HF, Hall A (1992b) Intracellular localization of the p21rho proteins. J Cell Biol 119:617–627.CrossRefGoogle Scholar
  3. Adini I, Rabinovitz I., Sun JF, Prendergast GC, Benjamin LE (2003) RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev 17:2721–2732.PubMedCrossRefGoogle Scholar
  4. Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T (2002) Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 8:2225–2232.PubMedGoogle Scholar
  5. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG (1996) The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727–1730.PubMedGoogle Scholar
  6. Bishop AL, Hall A (2000) Rho GTPases and their effector proteins. Biochem J 348(Pt 2):241–255.PubMedCrossRefGoogle Scholar
  7. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689.PubMedGoogle Scholar
  8. Chauhan S, Kunz S, Davis K et al (2004) Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem 279:937–944.PubMedCrossRefGoogle Scholar
  9. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM (2000) Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 275:17974–17978.PubMedCrossRefGoogle Scholar
  10. Cox AD, Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333:F51–F71.PubMedGoogle Scholar
  11. Delarue FL, Adnane J, Joshi B et al (2007) Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 26:633–640.PubMedCrossRefGoogle Scholar
  12. Delarue FL, Taylor BS, Sebti SM (2001) Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells. Oncogene 20:6531–6537.PubMedCrossRefGoogle Scholar
  13. Du W, Lebowitz PF, Prendergast GC (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831–1840.PubMedGoogle Scholar
  14. Du W, Prendergast GC (1999) Geranylgeranylated RhoB mediates inhibition of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res. 59:5924–5928.Google Scholar
  15. DuHadaway JB, Du W, Donover S et al (2003) Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene 22:3578–3588.PubMedCrossRefGoogle Scholar
  16. Ellenbroek SI, Collard JG (2007) Rho GTPases: functions and association with cancer. Clin Exp Metastasis 24:657–672.PubMedCrossRefGoogle Scholar
  17. Elliott K, Sakamuro D, Basu A et al (1999) Bin1 functionally interacts with Myc in cells and inhibits cell proliferation by multiple mechanisms. Oncogene 18:3564–3573.PubMedCrossRefGoogle Scholar
  18. Ellis S, Mellor H (2000) Regulation of endocytic traffic by rho family GTPases. Trends Cell Biol 10:85–88.PubMedCrossRefGoogle Scholar
  19. Engel ME, Datta PK, Moses HL (1998) RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. J Biol Chem 273:9921–9926.PubMedCrossRefGoogle Scholar
  20. Evangelista M, Zigmond S, Boone C (2003) Formins: signaling effectors for assembly and polarization of actin filaments. J Cell Sci 116:2603–2611.PubMedCrossRefGoogle Scholar
  21. Fernandez-Borja M, Janssen L, Verwoerd D, Hordijk P, Neefjes J (2005) RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. J Cell Sci 118:2661–2670.PubMedCrossRefGoogle Scholar
  22. Flynn P, Mellor H, Casamassima A, Parker PJ (2000) Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase. J Biol Chem 275:11064–11070.PubMedCrossRefGoogle Scholar
  23. Forget MA, Desrosiers RR, Del M et al (2002) The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis 19:9–15.PubMedCrossRefGoogle Scholar
  24. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B (2002) Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87:635–644.PubMedCrossRefGoogle Scholar
  25. Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687.PubMedCrossRefGoogle Scholar
  26. Fritz G, Kaina B (2000) Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem Biophys Res Commun 268:784–789.PubMedCrossRefGoogle Scholar
  27. Fritz G, Kaina B (2001) Ras-related GTPase Rhob represses NF-kappaB signaling. J Biol Chem 276:3115–3122.PubMedCrossRefGoogle Scholar
  28. Fritz G, Kaina B, Aktories K (1995) The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 270:25172–25177.PubMedCrossRefGoogle Scholar
  29. Fukumoto Y, Kaibuchi K, Hori Y, Fet al (1990) Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like GTP-binding proteins. Oncogene 5:1321–1328.PubMedGoogle Scholar
  30. Gampel A, Parker PJ, Mellor H (1999) Regulation of epidermal growth factor receptor traffic by the small GTPase rhoB. Curr Biol 9:955–958.PubMedCrossRefGoogle Scholar
  31. Gerhard R, Tatge H, Genth H et al (2005) Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB. J Biol Chem 280:1499–1505.PubMedCrossRefGoogle Scholar
  32. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316.PubMedGoogle Scholar
  33. Huang M, Duhadaway JB, Prendergast GC, Laury-Kleintop LD (2007) RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 27:2597–2605.PubMedCrossRefGoogle Scholar
  34. Huang M, Kamasani U, Prendergast GC (2006) RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 25:1281–1289.PubMedCrossRefGoogle Scholar
  35. Huang M, Prendergast GC (2006) RhoB in cancer suppression. Histol Histopathol 21:213–218.PubMedGoogle Scholar
  36. Huelsenbeck J, Dreger SC, Gerhard R, Fritz G, Just I, Genth H (2007) Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry 46:4923–4931.PubMedCrossRefGoogle Scholar
  37. Jaffe AB, Hall A (2002) Rho GTPases in transformation and metastasis. Adv Cancer Res 84:57–80.PubMedCrossRefGoogle Scholar
  38. Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269.PubMedCrossRefGoogle Scholar
  39. Jahner D, Hunter T (1991) The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 11:3682–3690.PubMedGoogle Scholar
  40. Jiang K, Delarue FL, Sebti SM (2004a) EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23:1136–1145.CrossRefGoogle Scholar
  41. Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S (2004b) Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24:5565–5576.CrossRefGoogle Scholar
  42. Kamasani U, Duhadaway JB, Alberts AS, Prendergast GC (2007) mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther 6:1422–1427.PubMedCrossRefGoogle Scholar
  43. Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC (2004) Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res 64:8389–8396.PubMedCrossRefGoogle Scholar
  44. Kamasani U, Liu AX, Prendergast GC (2003) Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther 2:273–280.PubMedGoogle Scholar
  45. Kamasani U, Prendergast GC (2005) Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer’s disease. Cancer Biol Ther 4:282–288.PubMedCrossRefGoogle Scholar
  46. Karnoub AE, Symons M, Campbell SL, Der CJ (2004) Molecular basis for Rho GTPase signaling specificity. Breast Cancer Res Treat 84:61–71.PubMedCrossRefGoogle Scholar
  47. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ (1995) Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15:6443–6453.PubMedGoogle Scholar
  48. Lajoie-Mazenc I, Tovar D, Penary M et al (2008) MAP1A light chain-2 interacts with GTP-RHOB to control EGF-dependent EGF-R signaling. J Biol Chem 283:4155–4164PubMedCrossRefGoogle Scholar
  49. Lebowitz P, Prendergast GC (1998) Functional interaction between RhoB and the transcription factor DB1. Cell Adhes Comm 4:1–11.Google Scholar
  50. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997a) Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272:15591–15594.CrossRefGoogle Scholar
  51. Lebowitz PF, Davide JP, Prendergast GC (1995) Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613–6622.PubMedGoogle Scholar
  52. Lebowitz PF, Du W, Prendergast GC (1997b) Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem 272:16093–16095.CrossRefGoogle Scholar
  53. Lebowitz PF, Prendergast GC (1998) Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17:1439–1445.PubMedCrossRefGoogle Scholar
  54. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC (2000) RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105–6113.PubMedCrossRefGoogle Scholar
  55. Liu A, Prendergast GC (2000) Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett 481:205–208.PubMedCrossRefGoogle Scholar
  56. Liu AX, Rane N, Liu JP, Prendergast GC (2001a) RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol 21:6906–6912.CrossRefGoogle Scholar
  57. Liu A, Cerniglia GJ, Bernhard EJ, Prendergast GC (2001b) RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A 98:6192–6197.CrossRefGoogle Scholar
  58. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7:535–545.PubMedCrossRefGoogle Scholar
  59. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202.PubMedCrossRefGoogle Scholar
  60. Mayo MW, Wang CY, Cogswell PC et al (1997) Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–1815.PubMedCrossRefGoogle Scholar
  61. Mazieres J, Antonia T, Daste G et al (2004) Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 10:2742–2750.PubMedCrossRefGoogle Scholar
  62. Mazieres J, Tillement V, Allal C et al (2005) Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp Cell Res 304:354–364.PubMedCrossRefGoogle Scholar
  63. Mazieres J, Tovar D, He B et al (2007) Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer 7:220.PubMedCrossRefGoogle Scholar
  64. Mellor H, Flynn P, Nobes CD, Hall A, Parker PJ (1998) PRK1 is targeted to endosomes by the small GTPase, RhoB. J Biol Chem 273:4811–4814.PubMedCrossRefGoogle Scholar
  65. Michaelson D, Silletti J, Murphy G, D’Eustachio P, Rush M, Philips MR (2001) Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol 152:111–126.PubMedCrossRefGoogle Scholar
  66. Mijimolle N, Velasco J, Dubus P et al (2005) Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7:313–324.PubMedCrossRefGoogle Scholar
  67. Milia J, Teyssier F, Dalenc F et al (2005) Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ 12:492–501.PubMedCrossRefGoogle Scholar
  68. Miura Y, Kikuchi A, Musha T et al (1993) Regulation of morphology by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in Swiss 3T3 cells. J Biol Chem 268:510–515.PubMedGoogle Scholar
  69. Neel NF, Lapierre LA, Goldenring JR, Richmond A (2007) RhoB plays an essential role in CXCR2 sorting decisions. J Cell Sci 120:1559–1571.PubMedCrossRefGoogle Scholar
  70. Palazzo A, Cook TA, Alberts AS, Gundersen GG (2001) mDia mediates Rho-regulated formation and orientation of stable microtubules. Nature Cell Biol. 3:723–729.PubMedCrossRefGoogle Scholar
  71. Pan J, She M, Xu ZX, Sun L, Yeung SC (2005) Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 65:3671–3681.PubMedCrossRefGoogle Scholar
  72. Pan J, Yeung SC (2005) Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 65:9109–9112.PubMedCrossRefGoogle Scholar
  73. Prendergast GC (2000) Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12:166–173.PubMedCrossRefGoogle Scholar
  74. Prendergast GC (2001) Actin’ up: RhoB in cancer and apoptosis. Nat Rev Cancer 1:162–168.PubMedCrossRefGoogle Scholar
  75. Prendergast GC, Oliff A (2000) Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin Cancer Biol 10:443–452.PubMedCrossRefGoogle Scholar
  76. Prendergast GC, Rane N (2001) Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs 10:2105–2116.PubMedCrossRefGoogle Scholar
  77. Pruitt K, Der CJ (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171:1–10.PubMedCrossRefGoogle Scholar
  78. Pruyne D, Evangelista M, Yang C et al (2002) Role of formins in actin assembly: nucleation and barbed-end association. Science 297:612–615.PubMedCrossRefGoogle Scholar
  79. Raponi M, Harousseau JL, Lancet JE et al (2007) Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 13:2254–2260.CrossRefGoogle Scholar
  80. Raponi M, Lancet JE, Fan H et al (2008) A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111:2589–2596.CrossRefGoogle Scholar
  81. Ridley, A. J. 2004. Rho proteins and cancer. Breast Cancer Res Treat 84:13–19.PubMedCrossRefGoogle Scholar
  82. Robertson D, Paterson HF, Adamson P, Hall A, Monaghan P (1995) Ultrastructural localization of ras-related proteins using epitope-tagged plasmids. J Histochem Cytochem 43:471–480.PubMedGoogle Scholar
  83. Sahai E, Marshall CJ (2002) Rho GTPases and cancer. Nature Rev Cancer 2:133–142.CrossRefGoogle Scholar
  84. Sakamuro D, Elliott K, Wechsler-Reya R, Prendergast GC (1996) BIN1 is a novel MYC-interacting protein with features of a tumor suppressor. Nature Genet. 14:69–77.PubMedCrossRefGoogle Scholar
  85. Sandilands E, Akbarzadeh S, Vecchione A, McEwan DG, Frame MC, Heath JK (2007) Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep 8:1162–1169.PubMedCrossRefGoogle Scholar
  86. Sandilands E, Cans C, Fincham VJ et al (2004) RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell 7:855–869.PubMedCrossRefGoogle Scholar
  87. Sato N, Fukui T, Taniguchi T et al (2007) RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line. Int J Cancer 120:543–551.PubMedCrossRefGoogle Scholar
  88. Schubbert S, Bollag G, Shannon K (2007) Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev 17:15–22.PubMedCrossRefGoogle Scholar
  89. Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs 9:2767–2782.PubMedCrossRefGoogle Scholar
  90. Shen M, Feng Y, Gao C et al 2004. Detection of cyclin B1 expression in G(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res 64:1607–1610.PubMedCrossRefGoogle Scholar
  91. Togel M, Wiche G, Propst F (1998) Novel features of the light chain of microtubule-associated protein MAP1B: microtubule stabilization, self interaction, actin filament binding, and regulation by the heavy chain. J Cell Biol 143:695–707.PubMedCrossRefGoogle Scholar
  92. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS (2000) Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. Mol Cell 5:13–25.PubMedCrossRefGoogle Scholar
  93. Trapp T, Olah L, Holker I et al (2001) GTPase RhoB: an early predictor of neuronal death after transient focal ischemia in mice. Mol Cell Neurosci 17:883–894.PubMedCrossRefGoogle Scholar
  94. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD (2002) Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 1:575–583.PubMedGoogle Scholar
  95. Wallar BJ, Deward AD, Resau JH, Alberts AS (2007) RhoB and the mammalian Diaphanous-related formin mDia2 in endosome trafficking. Exp Cell Res 313:560–571.PubMedCrossRefGoogle Scholar
  96. Wang DA, Sebti SM (2005) Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. J Biol Chem 280:19243–19249.PubMedCrossRefGoogle Scholar
  97. Wang S, Yan-Neale Y, Fischer D et al (2003) Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene 22:6204–6213.PubMedCrossRefGoogle Scholar
  98. Wasserman S (1998) FH proteins as cytoskeletal organizers. Trends Cell Biol 8:111–115.PubMedCrossRefGoogle Scholar
  99. Watanabe N, Madaule P, Reid T et al (1997) p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. Embo J 16:3044–3056.PubMedCrossRefGoogle Scholar
  100. Weidle UH, Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20:1471–1485.PubMedGoogle Scholar
  101. Westmark CJ, Bartleson VB, Malter JS (2005) RhoB mRNA is stabilized by HuR after UV light. Oncogene 24:502–511.PubMedCrossRefGoogle Scholar
  102. Westwick JK, Lambert QT, Clark GJ et al (1997) Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 17:1324–1335.PubMedGoogle Scholar
  103. Wherlock M, Gampel A, Futter C, Mellor H (2004) Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J Cell Sci 117:3221–3231.PubMedCrossRefGoogle Scholar
  104. Whitehead IP, Abe K, Gorski JL, Der CJ (1998) CDC42 and FGD1 cause distinct signaling and transforming activities. Mol Cell Biol 18:4689–4697.PubMedGoogle Scholar
  105. Zalcman G, Closson V, Linares-Cruz G et al (1995) Regulation of Ras-related RhoB protein expression during the cell cycle. Oncogene 10:1935–1945.PubMedGoogle Scholar
  106. Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC (2003) Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene 22:1124–1134.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Minzhou Huang
    • 1
  • Lisa D. Laury-Kleintop
    • 1
  • George C. Prendergast
    • 2
  1. 1.Lankenau Institute for Medical ResearchWynnewoodUSA
  2. 2.Department of Pathology, Anatomy and Cell Biology and Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations